Scientists add second drug to standard chemo in fight against tough lymphoma
NCT ID NCT04214626
Summary
This study tested whether adding the drug lenalidomide to standard chemotherapy (R-CHOP) works better for people with medium-to-high risk diffuse large B-cell lymphoma. The trial involved 60 previously untreated patients to see if the combination improves how long patients live without their cancer getting worse. Researchers measured 2-year survival rates and monitored side effects of the treatment combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.